New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
OverviewChart

Quote Panel

Shape
Updated June 18, 2025
1W -4.36 % 1M 8.40 % 3M 10.58 % 1Y 148.02 %

Key Metrics

Shape

  • Market Cap

    64.99M

  • Shares Outstanding

    14.80M

  • Share in Float

    14.11M

  • Dividende

    0

  • Earning Date

    04 Aug 2025

  • Price Target

    4.39

  • Average Volume

    39717

  • Beta

    0.72

  • Range

    1-5.87

  • Industry

    Biotechnology

  • Website

    https://alteritytherapeutics.com

  • Sector

    Healthcare

Fundamentals

Shape

Relative Strength

Shape

ATHE

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$1M

Shape39%

2025-Revenue

$0.82

Shape-95%

2025-EPS

$670K

Shape82%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Benchmark

downgrade

Previous: Speculative Buy

2025-02-03

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

N/A

-0.00
vs -0.00

Q4.22

arrow
arrow

N/A

-0.00
vs -0.00

Q1.23

arrow
arrow

N/A

-0.00
vs NA

Q2.23

arrow
arrow

N/A

-0.00
vs -0.00

Q3.23

arrow
arrow

N/A

-0.00
vs NA

Q4.23

arrow
arrow

N/A

-0.00
vs -0.00

Q1.24

arrow
arrow

N/A

-0.00
vs -0.00

Q2.24

arrow
arrow

N/A

-0.00
vs -0.00

Q3.24

arrow
arrow

N/A

-0.00
vs -0.00

Q4.24

arrow
arrow

N/A

-0.00
vs -0.00

Sales GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

+13%

2.8M  vs 2.5M

Q4.22

arrow
arrow

+1%

2.4M  vs 2.4M

Q1.23

arrow
arrow

NA

765.2K  vs NA

Q2.23

arrow
arrow

-45%

1.5M  vs 2.8M

Q3.23

arrow
arrow

NA

950.4K  vs NA

Q4.23

arrow
arrow

-20%

1.9M  vs 2.4M

Q1.24

arrow
arrow

+38%

1.1M  vs 765.2K

Q2.24

arrow
arrow

+38%

2.1M  vs 1.5M

Q3.24

arrow
arrow

-16%

803K  vs 950.4K

Q4.24

arrow
arrow

-58%

803K  vs 1.9M

Return on EquityShape

status-upQoQ

Q2.21

arrow
arrow

-22%

-0.22
vs -0.25

Q4.21

arrow
arrow

-16%

-0.16
vs -0.22

Q2.22

arrow
arrow

-18%

-0.18
vs -0.16

Q4.22

arrow
arrow

-29%

-0.29
vs -0.18

Q2.23

arrow
arrow

-25%

-0.25
vs -0.29

Q4.23

arrow
arrow

-37%

-0.37
vs -0.25

Q2.24

arrow
arrow

-91%

-0.91
vs -0.37

Q4.24

arrow
arrow

-92%

-0.92
vs -0.91

Institutionnal OwnershipShape

status-upQoQ

Q2.23

arrow
arrow

7

7
vs 7

NA

Q3.23

arrow
arrow

8

8
vs 7

14%

Q4.23

arrow
arrow

9

9
vs 8

13%

Q1.24

arrow
arrow

10

10
vs 9

11%

Q2.24

arrow
arrow

10

10
vs 10

NA

Q3.24

arrow
arrow

12

12
vs 10

20%

Q4.24

arrow
arrow

12

12
vs 12

NA

Q1.25

arrow
arrow

11

11
vs 12

-8%

Earnings Growth

Latest News

ATHE

globenewswire.com

7 hours ago

Alterity Therapeutics Prominently Featured at the International MSA Congress
ATHE

globenewswire.com

7 hours ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
ATHE

globenewswire.com

7 hours ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
ATHE

globenewswire.com

7 hours ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
ATHE

globenewswire.com

7 hours ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
ATHE

globenewswire.com

8 hours ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress